Britton Chance Distinguished Lecture in Engineering and Medicine
Morton Goldberg Professor and Director
Translational Tissue Engineering Center
Johns Hopkins University
“Regenerative Immunology: The Role of Technology Translation in Guiding Discovery”
Wednesday, January 29, 2020, 3:00 PM, Wu and Chen Auditorium, Levine Hall
Biomaterial implants have a long history in the clinic but regenerative biomaterials and regenerative medicine therapies in general have been slow to reach patients. Clinical translation provides a unique and critical opportunity to investigate the key therapeutic drivers of technology efficacy in people. Careful evaluation of clinical outcomes and (re)evaluation of design parameters is central to improving research and technology development. A key outcome of our clinical translation experiences in orthopedics and plastic surgery was the unexpected discovery of adaptive immune cells around synthetic implants. We are now working to understand the role of the immune system and cellular senescence in the biomaterial response and repair across different tissues. This new therapeutic target serves as the basis for the design of regenerative immunotherapies.
Jennifer Elisseeff is the Morton Goldberg Professor and Director of the Translational Tissue Engineering Center at Johns Hopkins’ Department of Biomedical Engineering and the Wilmer Eye Institute with appointments in Chemical and Biological Engineering, Materials Science and Orthopedic Surgery. She received a bachelor’s degree in chemistry from Carnegie Mellon University and a PhD in Medical Engineering from the Harvard–MIT Division of Health Sciences and Technology. She was a Fellow at the National Institute of General Medical Sciences, Pharmacology Research Associate Program, where she worked in the National Institute of Dental and Craniofacial Research.
Dr. Elisseeff is committed to the translation of regenerative biomaterials and has founded several companies and participates in several industry advisory boards including the State of Maryland’s Technology Development Corporation (TEDCO). She was elected a Fellow of the American Institute of Medical and Biological Engineering, the National Academy of Inventors, and a Young Global Leader by World Economic Forum. In 2018, she was elected to the National Academy of Engineering and National Academy of Medicine.
Previous Britton Chance Distinguished Lecturers
1995: Lewis S. Edelheit, General Electric Company
1996: Douglas A. Lauffenburger, Massachusetts Institute of Technology
1998: George Georgiou, University of Texas at Austin
1999: Jeffrey A. Hubbell, University of Zürich
2000: W. Mark Saltzman, Cornell University
2001: Chaitan S. Khosla, Stanford University
2002: Sangtae Kim, Lilly Research Laboratories
2003: Larry V. McIntire, Rice University
2004: Deborah E. Leckband, University of Illinois at Urbana-Champaign
2004: Stephen R. Quake, Stanford University
2005: Frances H. Arnold, California Institute of Technology
2006: Adam P. Arkin, University of California at Berkeley
2007: Kristi S. Anseth, University of Colorado at Boulder
2008: Jay D. Keasling, University of California at Berkeley
2009: Mark E. Davis, California Institute of Technology
2010: David A. Tirrell, California Institute of Technology
2011: Frank S. Bates, University of Minnesota
2012: Arup K. Chakraborty, Massachusetts Institute of Technology
2013: Melody A. Swartz, Ecole polytechnique federale de Lausanne
2014: James C. Liao, University of California, Los Angeles
2015: Samir Mitragotri, University of California, Santa Barbara
2016: David Mooney, Harvard School of Engineering and Applied Science
2017: Lynda G. Griffith, Massachusetts Institute of Technology
2018: David Schaffer, University of California at Berkeley
This distinguished lecture honors Britton Chance
Britton Chance (1913-2010) was a world leader in transforming theoretical science into useful biomedical and clinical applications. Among his pioneering contributions to fundamental biomedical science were his discovery of numerous enzyme-substrate compounds, World War II development of computers for Radar, the elucidation of the fundamental principles of control of bioenergetics and metabolism, the first human subject study using 31P NMR (phosphorous nuclear magnetic resonance) spectroscopy and more recently optical spectroscopy and imaging of human brain and breast. Through decades of scholarly mentorship of colleagues in disciplines ranging from mathematics to clinical medicine, he brought additional distinction to this University and multiplied its contributions to improving the human condition.
Professor Chance was Eldridge Reeves Johnson University Professor of Biophysics, Physical Chemistry and Radiologic Physics at Penn. He received his undergraduate degree from Penn’s Towne Scientific School in 1935 and doctoral degrees from both Penn and the University of Cambridge. He was a member of the National Academy of Sciences and of the Institute of Medicine and a Foreign Member of the Royal Society of London. Among very many other recognitions, he received the National Medal of Science, the Benjamin Franklin Medal from the American Philosophical Society, the Biological Physics Prize from the American Physical Society, and honorary degrees from the Karolinska Institut, the Medical College of Ohio at Toledo, Semmelweis University, Hahnemann Medical College and the Universities of Pennsylvania, Helsinki, Dusseldorf and Buenos Aires. In his honor, Huazhong University of Science and Technology named a major laboratory as the Britton Chance Center for Biomedical Photonics.